Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.70 |
| ▸ | CES1 | P23141 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 6/20 | 0.67 |
| ▸ | CA2 | P00918 | 6/20 | 0.67 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.64 |
| ▸ | PARP1 | P09874 | 1/20 | 0.64 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.64 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | PLK1 | P53350 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879646 | 0.84 | CES2 (0.52) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL9418310 | 0.82 | RXFP1 (0.79) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL557152 | 0.82 | CES2 (1.00) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL51509 | 0.82 | RXFP1 (0.79) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL14507040 | 0.82 | CES2 (1.00) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL12341379 | 0.81 | CES2 (0.69) | CES2CES1CA1CA2PARP10 | |
| P-Anisic Acid SCHEMBL1157044 | 0.80 | CA1 (1.00) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL29548151 | 0.80 | CES2 (0.95) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL55537 | 0.80 | CES2 (0.70) | CES2CES1CA1CA2PARP10 | |
| P-Methoxy-Acetophenone SCHEMBL41285 | 0.80 | MAPT (0.70) | CES2CES1CA1CA2PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022270628-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | 国立大学法人 大分大学 | 2022-12-29 | — | — | WO | disclosed |
| US-11177450-B2 | Organoelectroluminescent element, and light emission device, display device, and illumination device in which said organoelectroluminescent element is used | UDC IRELAND LIMITED (IE) | 2021-11-16 | — | — | US | disclosed |
| US-10292972-B1 | Pharmaceutical composition for treating cancer and a method thereof | KING ABDULAZIZ UNIVERSITY (SA) | 2019-05-21 | — | — | US | disclosed |
| US-20190125732-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND A METHOD THEREOF | KING ABDULAZIZ UNIVERSITY (SA) | 2019-05-02 | — | — | US | disclosed |
| US-8394935-B2 | Method for producing furanose derivative | API CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-7951950-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100298550-A1 | PROCESS FOR PRODUCTION OF RIBOFURANOSE DERIVATIVES | API CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2210896-A1 | PROCESS FOR PRODUCTION OF RIBOFURANOSE DERIVATIVES | API Corporation (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20100105890-A1 | METHOD FOR PRODUCING FURANOSE DERIVATIVE | API CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2105445-A1 | METHOD FOR PRODUCTION OF FURANOSE DERIVATIVE | API Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-6730810-B2 | HOMOGENOUS MIXTURE COMPRISING ACID HALIDE WITH HYDROXY CARBOXYLIC ACIDS AND ANHYDRIDE; DISCOLORATION INHIBITION | HUNTSMAN PETROCHEMICAL CORPORATION | 2004-05-04 | — | — | US | disclosed |
| US-20030120089-A1 | Anhydride stabilization | HUNTSMAN PETROCHEMICAL CORPORATION | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120089-A1 | Anhydride stabilization | CA7, CA4, CA9 | CES2 2674/4885CES1 2816/4885CA1 8/4885 |
| US-10292972-B1 | Pharmaceutical composition for treating cancer and a method thereof | SYMPK, ITPA, HRAS | CES2 4043/4885CES1 2082/4885CA1 372/4885 |
| US-20190125732-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND A METHOD THEREOF | SYMPK, ITPA, HRAS | CES2 4043/4885CES1 2082/4885CA1 372/4885 |
| US-20100298550-A1 | PROCESS FOR PRODUCTION OF RIBOFURANOSE DERIVATIVES | RNASEL, RPIA, RIOX2 | CES2 1880/4885CES1 1639/4885CA1 1805/4885 |
| US-20100105890-A1 | METHOD FOR PRODUCING FURANOSE DERIVATIVE | DERA, ALDOA, DPYD | CES2 1208/4885CES1 745/4885CA1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.